Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06309199

Prevalence of FGIDs and Probiotics Study

This is a study to evaluate the prevalence of FGIDs in infants using the Thai version of Rome IV diagnostic questionnaire for functional gastrointestinal disorders in infants and evaluate the efficacy of Limosilactobacillus reuteri DSM 17938 to prevent FGIDs in infants.

Recruiting

Interested in participating?

Request Info

Key information

Age range

3 day–1 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Maha Chakri Sirindhorn Clinical Research Center (Chula CRC)

Bangkok, 10330, Thailand

Location status: Recruiting

Location contact

CONTACT

02 251 6704

About this study

This is a randomized controlled trial study about the the efficacy of Lactobacillus reuteri DSM 1987 to prevent FGIDs in healthy infants and the effect to gut microbiota diversity. The incidence of FGIDs in Thai infant using Thai version of ROME IV questionnaire (authorized by Rome Foundation) for infant and toddler and the associated factors of FGIDs also evaluate.

Population: target and control populations are the healthy infants born at King Chulalongkorn Memorial Hospital, Bangkok, Thailand, and can come to follow up at the hospital at 1, 2, 4, and 12 months of age Inclusion criteria

  • Healthy and term (GA 37-41 weeks) infants
  • Appropriate weight for age
  • APGAR score more than 8 at 10 minutes of life
  • Normal physical examination
  • Mothers have no previous probiotics use Methodology
  • Participants were double-blinded randomized using computer generation in block of four
  • Target population were received Limosilactobacillus reuteri DSM 17938 5 drops (0.185 mL) per day for 60 days
  • Control population were received mixture of sunflower oil and MCT oil 5 drop (0.185 mL) per day for 60 days
  • There were 5 visits at birth, 1, 2, 4, 12 months of life: the demographic data/Rome IV questionnaire for FGIDs in infant and associated factors with FGIDs record, physical examination and stool collection The study will be analyzed (open the randomized group) after all participants complete the 4-month follow-up period
  • Research assistance will telephone to them to take the Rome IV questionnaire for FGIDs at 3, 6, 9 months of life

Biological specimen collection Stool will be collected by rectal stimulation in each visit. The amount of >5 gm stool will be preserved in DNA and kept at -80 °C. All stool specimen will be processed the DNA extraction (DNA > 40 microlitre with concentration >50 ng/L). The DNA extraction for further amplification 16S rRNA using Illumina. The rest of the specimen will be kept up to 10 years for further evaluation.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy and term (GA 37-41 weeks) infants
  • Appropriate weight for age
  • APGAR score more than 8 at 10 minutes of life
  • Normal physical examination
  • Mothers have no previous probiotics use

Exclusion criteria

  • not willing to anticipate in the study
  • cannot come to follow-up until 1 year of age

Treatment and study plan

Biogaia

Dietary Supplement

Biogaia is a probiotics product that contain Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil

Placebo

Other

Limosilactobacillus reuteri DSM 17938, sunflower oil and MCT oil

Other names: Sunflower oil + MCT oil

Primary outcomes

  1. The prevalence of functional gastrointestinal disorders in the treatment group

    Time frame: at birth, 1 month, 2 months, 4 months

    Functional gastrointestinal disorders (colic, regurgitation, constipation, dyschazia and rumination) were assessed using the Thai version of Rome IV diagnostic questionnaire for neonates and toddlers

Secondary outcomes

  1. The prevalence of functional gastrointestinal disorders in the placebo group

    Time frame: at birth, 1 month, 2 months, 4 months and 1 year (5-time points)

    Functional gastrointestinal disorders (include colic, regurgitation, constipation, dyschazia and rumination) were assessed using the Thai version of Rome IV diagnostic questionnaire for neonates and toddlers

  2. The prevalence of functional gastrointestinal disorders in the treatment group

    Time frame: at 1 year of age

    Functional gastrointestinal disorders (colic, regurgitation, constipation, dyschazia and rumination) were assessed using the Thai version of Rome IV diagnostic questionnaire for neonates and toddlers

Other outcomes

  1. Nutrition associated with functional gastrointestinal disorders in infants

    Time frame: at 1 year

    Amount of food composition (carbohydrate, protein, lipid - present as gm per kg body weight)

  2. Gut microbial profiles associated with functional gastrointestinal disorder in infants

    Time frame: at birth, 1 month, 2 months, and 4 months

    Comparative metagenomic analysis of gut microbial profiles (diversity, relative abundance, species alteration) in fecal samples among different groups of infants

  3. The sleep quality assessed by Brief Infant Sleep Revise Questionnaire of BISQR

    Time frame: at birth, 1 month, 2 months, 4 months and 1 year (5-time points)

    The questionnaire has 33 items in 3 main categories (Infant sleep, parent perception and parent behavior). Scores on each subscale and the total score are scaled from 0 to 100. Higher score denote better sleep quality.

  4. Stool metabolomic substances (i.e microbial conjugation of secondary bile acid, aminoacid) and the stool metabolites alteration

    Time frame: at birth, 1 month, 2 months and 4 months

    Fecal metabolomic substances (i.e microbial conjugation of secondary bile acid, aminoacid) were assesse using liquid chromatography-mass spectrometry (LC-MS), gas chromatography-mass spectrometry (GC-MS) and capillary electrophoresis-mass spectrometry (CE-MS)

  5. Fluid intake associated with functional gastrointestinal disorders in infants

    Time frame: at birth, 1 month, 2 months and 4 months and 1 year (5-time points)

    type of milk (breastfeeding or formula or mixed) and amount (mL per kg body weight)

  6. Stress associated with functional gastrointestinal disorders in infants

    Time frame: at birth and 1 year

    stress in family (i.e divorce, family dept present as yes or no)

  7. Antibiotics associated with functional gastrointestinal disorders in infants

    Time frame: at birth, 1 month, 2 months and 4 months and 1 year (5-time points)

    antibiotics use (yes or no)

  8. Economic status associated with functional gastrointestinal disorders in infants

    Time frame: at birth and 1 year

    Economics status (income in baht)

  9. Education of caregiver associated with functional gastrointestinal disorders in infants

    Time frame: at birth and 1 year

    Education (low, high)

  10. Serious adverse effect during follow-up until end point

    Time frame: 1 month, 2 months, 4 months, 6 months, 9 months, 1 years

    admission, cause of admission, treatment details (intravenous fluid, medication, oxygen supplementation)

  11. skin problems (seborrheic dermatitis, atopic dermatitis, nonspecific dermatitis)

    Time frame: 1 month, 2 months, 4 months, 1 year

    patient oriented- Scoring atopic dermatitis (it is an application in phone to add the information of skin lesion by doctor or parent examination), examination and record the characteristics and location of skin lesion by doctors

Study contacts

Contact information is provided by the study sponsor or research team.

Palittiya Sintusek, PhD

CONTACT

[email protected]

+66818288082

Sittichoke Prachuapthunyachart, MD

CONTACT

[email protected]

+66829740649

Sponsors and collaborators

Lead sponsor

Chulalongkorn University

Other

Registry information

Official study title

Center of Excellence in Thai Pediatric Gastroenterology, Hepatology and Immunology

Acronym: PROOF

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Mar 13, 2024
Registry last updated
Jul 2, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.